S&P 500   4,577.11
DOW   35,368.47
QQQ   370.55
Is Lowe’s A Buy On Pre-Earnings Weakness? 
Has Sherwin-Williams Company Lost Its Luster? 
Bed Bath & Beyond Stock is Pricing Right
MarketBeat Podcast: Market Volatility and Commodites Options
Microsoft buys game maker Activision Blizzard for about $70B
Truist cuts down overdraft fees, joining other big banks
Polish chief auditor seeks to question leader over spying
S&P 500   4,577.11
DOW   35,368.47
QQQ   370.55
Is Lowe’s A Buy On Pre-Earnings Weakness? 
Has Sherwin-Williams Company Lost Its Luster? 
Bed Bath & Beyond Stock is Pricing Right
MarketBeat Podcast: Market Volatility and Commodites Options
Microsoft buys game maker Activision Blizzard for about $70B
Truist cuts down overdraft fees, joining other big banks
Polish chief auditor seeks to question leader over spying
S&P 500   4,577.11
DOW   35,368.47
QQQ   370.55
Is Lowe’s A Buy On Pre-Earnings Weakness? 
Has Sherwin-Williams Company Lost Its Luster? 
Bed Bath & Beyond Stock is Pricing Right
MarketBeat Podcast: Market Volatility and Commodites Options
Microsoft buys game maker Activision Blizzard for about $70B
Truist cuts down overdraft fees, joining other big banks
Polish chief auditor seeks to question leader over spying
S&P 500   4,577.11
DOW   35,368.47
QQQ   370.55
Is Lowe’s A Buy On Pre-Earnings Weakness? 
Has Sherwin-Williams Company Lost Its Luster? 
Bed Bath & Beyond Stock is Pricing Right
MarketBeat Podcast: Market Volatility and Commodites Options
Microsoft buys game maker Activision Blizzard for about $70B
Truist cuts down overdraft fees, joining other big banks
Polish chief auditor seeks to question leader over spying
Lowest-Rated Stocks  
NASDAQ:ESPR

Esperion Therapeutics Income Statement & Balance Sheet

$3.73
-0.20 (-5.09%)
(As of 01/18/2022 04:00 PM ET)
Add
Compare
Today's Range
$3.72
▼
$3.94
50-Day Range
$3.73
▼
$10.02
52-Week Range
$3.71
▼
$39.49
Volume
1.11 million shs
Average Volume
1.35 million shs
Market Capitalization
$108.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.79

Esperion Therapeutics (NASDAQ:ESPR) Income Statement, Balance Sheet and Cash Flow Statement

This page was last updated on 1/19/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.